97. Ulcerative colitis Clinical trials / Disease details
Clinical trials : 2,630 / Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2022-000837-17-NL (EUCTR) | 07/12/2022 | 29/09/2022 | Lengthening of vedolizumab injections based on drug concentrations in patients with inflammatory bowel disease | Subcutaneous vedolizumab drug de-escalation using therapeutic drug monitoring in inflammatory bowel disease: a randomized controlled pilot study - SILVER-study | Inflammatory bowel diseases (Crohn's disease, ulcerative colitis);Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Trade Name: Vedolizumab, Entyvio | Amsterdam UMC | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 40 | Phase 4 | Netherlands |